Introduction
Many people with type 2 diabetes mellitus (T2DM) require multiple daily injections (MDI) of insulin when diet, lifestyle and oral agents no longer provide adequate glycemic control. 1 Unfortunately taking MDI can be challenging and patient compliance and persistence with this therapy is frequently suboptimal. 2 As a result many people using MDI therapy do not achieve target glycemic control. 3 Continuous subcutaneous insulin infusion (CSII) using insulin pumps decreases many of the barriers associated with MDI, i.e., discreet and no daily insulin injections. Several studies have assessed CSII in people with T2DM and have shown improved blood glucose control and improved quality of life compared to when they were receiving their MDI therapy. However, due to complexities and costs associated with insulin pumps, they have not been adopted for use in people with T2DM. 4 CeQur has developed PaQ, a simple 3-day insulin delivery device. PaQ was designed to reduce the barriers to MDI therapy for people with T2DM. PaQ is a small, discreet, wearable device that delivers both basal (CSII at a pre-set rate) and bolus insulin (additional insulin self administered at mealtime) without the need of daily injections. PaQ has two components, a disposable single-use Reservoir Unit and a re-usable Messenger Unit. A soft polymeric cannula is inserted subcutaneously, through the Infuser Unit, allowing insulin delivery without a separate infusion set. PaQ provides a contant basal infusion of insulin at one of 7 preset basal rates; 16, 20, 24, 32, 40, 50, or 60 units/day. By pushing a Bolus Button, PaQ also provides meal time bolus insulin, 2 units with each push of the button. PaQ can deliver up to 330 insulin units of rapid acting insulin (100 unit/mL) over 3 days. The Messenger Unit, with a push of the Status Button, communicates the length of time worn, if the fluid path is blocked, or if the device is running out of insulin.
PaQ Functionality
When a user fills PaQ with insulin, the insulin fills and expands an elastomeric bladder (Insulin Reservoir). The pressure from the elastomeric bladder pushes the insulin through precise microcapillary flow restrictors, manufactured to control insulin flow at the pre-set basal rate. The key to this basal technology is the proprietary manufacturing methods developed to create the pre-set basal rates as low as 6.7 µl/hr, with an accuracy of ±10%. With each press of the Bolus Button, a piston pump delivers 2 units ± 10% of insulin from the elastomeric bladder. The device generates a tactile feedback when the Bolus Button is pressed completely, providing dosing confidence to the user.
Figure 1-PaQ, Simple 3-day insulin delivery device
The Messenger Unit senses pressure from the basal flowpath and is able to determine if the insulin delivery is as expected, if the PaQ is running out of insulin, or if it is occluded. The Messenger also tracks the time the user has worn the device. This information or the status of the device can be learned with the press of the Status Button by the user. The status is communicated primarily through vibratory pulses.
Figure 2 -PaQ Components
The basal flow is administered as a continuous infusion of insulin for 3 days at a preset rate, set in terms of units per day of insulin. The basal rate of PaQ has been tested according to IEC 60601-2-24, using the test methods for a type 1 infusion pump for ambulatory use, to verify the overall percentage flow error is within ± 10% of the target set basal rate. The accuracy of bolus dose administration has been tested according to the test set-up described in IEC 60601-2-24, Particular requirements for the safety of infusion pumps and controllers. Overall bolus dose accuracy is ± 10%.
Methods
To determine feasibility of use and performance of PaQ twenty patients with T2DM on a MDI regimen with HbA1c ≤9% were enrolled into a single center, single arm study. The study was comprised of three 2-week periods; baseline (MDI therapy), transition (from MDI to PaQ) and PaQ treatment. Feasibility of use endpoints included; ability to assemble, use and change PaQ. Transition was assessed by days required, number of basal rates and total daily dose of insulin (TDD) used. Efficacy assessments included; self monitored blood glucose and continuous glucose monitoring. Safety was assessed using site examination, hypoglycemic episodes and adverse device effects (ADEs).
Results
Eighteen patients completed the study. All were able to assemble and use PaQ after 1 hour of training. Approximately 75% of patients successfully transitioned from MDI to PaQ with the first PaQ basal rate selected. Mean TDD for all patients at the end of PaQ therapy (57±15 U) was not different from baseline (60±19 U). Changes in self-monitored blood glucose values (mean ± SD mg/dL) during PaQ therapy showed a trend toward better glycemic control compared to baseline. In addition, the data from the PaQ Satisfaction and Acceptance questionnaire supported very high device satisfaction and acceptance for the PaQ device.
Conclusions
These findings which suggest ease of use, reduction of barriers to insulin therapy and a trend toward a slight improvement in glycemic control are important because improved patient medication experience may result in better compliance and subsequent clinical outcomes.
